Latest Ratios: P/E Ratio -1.5x · EV/EBITDA N/A · ROE -32.5%. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $31M | $33M | $28M | $93M | — | — | — |
| Enterprise Value | $19M | $20M | $8M | $90M | — | — | — |
| P/E Ratio → | -1.46 | — | 2.39 | — | — | — | — |
| P/S Ratio | 7.27 | 7.60 | 12.55 | 22.07 | — | — | — |
| P/B Ratio | 0.51 | 0.54 | 0.40 | 2.50 | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.65 | 3.67 | 21.20 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | 0.67 | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | -249.6% | -249.6% | -803.2% | -103.8% | -153.2% | — | — |
| Operating Margin | -408.5% | -408.5% | -1289.4% | -200.9% | -547.3% | — | — |
| Net Profit Margin | -496.1% | -496.1% | 526.5% | -164.6% | -476.6% | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -32.5% | -32.5% | 21.8% | -23.1% | -35.6% | -96.3% | -2.9% |
| ROA | -31.3% | -31.3% | 20.3% | -20.3% | -31.3% | -83.5% | -2.6% |
| ROIC | -19.9% | -19.9% | -38.9% | -19.8% | -28.6% | -73.8% | -3.7% |
| ROCE | -26.5% | -26.5% | -51.8% | -26.5% | -38.6% | -88.0% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.06 | 0.06 | 0.11 | 0.01 |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.21 | -0.28 | -0.10 | -0.15 | -0.81 | -0.50 |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | -1.30 |
| Interest Coverage | — | — | 168.87 | — | — | — | — |
Net cash position: cash ($13M) exceeds total debt ($609000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 7.10 | 7.10 | 19.80 | 2.78 | 5.20 | — | — |
| Quick Ratio | 7.10 | 7.10 | 19.80 | 2.78 | 5.20 | — | — |
| Cash Ratio | 5.18 | 5.18 | 17.15 | 1.88 | 4.24 | — | — |
| Asset Turnover | — | 0.07 | 0.03 | 0.10 | 0.04 | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 41.9% | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | — | — | — | — | — | — |
| Shares Outstanding | — | $10M | $4M | $8M | $8M | $8M | $8M |
Persistent operating cash deficit
Based on reported figures, MDBH trades at a P/S ratio of 7.27, which appears disconnected from its negative profitability profile and suggests that investors are pricing the firm as a speculative venture rather than a traditional financial services entity with predictable cash flows or earnings multiples.
The absence of a meaningful P/E ratio and the negative EBITDA highlight that standard valuation metrics are currently ineffective for assessing the firm's intrinsic value. Investors should monitor whether the market's willingness to pay a premium for revenue is predicated on the potential for a breakthrough in the technology development segment rather than the core broker-dealer business.
According to recent financial statements, MDBH's ROIC has remained consistently negative, reaching -7.1% in 2026Q1, which indicates that the firm is currently destroying shareholder value rather than compounding it through its dual-track investment banking and synthetic biology incubation model.
The persistent decay in returns on invested capital suggests that the capital allocated to technology development is not yet generating sufficient returns to offset the firm's high fixed-cost base. This trend warrants further investigation into whether the firm can achieve a positive return profile without a fundamental shift in its operational strategy.
As reported in quarterly filings, MDBH's asset turnover ratio has languished at approximately 0.05 in 2026Q1, which suggests that the firm's asset base is not being utilized efficiently to generate revenue relative to its peers in the capital markets industry.
The low turnover ratio implies that the firm's capital is tied up in assets that are not contributing to immediate top-line growth. This lack of efficiency appears to be a structural byproduct of the incubator model, where significant resources are committed to long-term research projects that remain pre-revenue.
Based on the provided balance sheet data, MDBH's current ratio has fluctuated significantly, yet the underlying cash position has steadily eroded, indicating that the firm's liquidity position is becoming increasingly vulnerable to the ongoing cash burn required to sustain its technology development operations.
While the current ratio appears high, it may be misleading if the underlying assets lack immediate liquidity or are tied to illiquid intellectual property. Investors should monitor the firm's ability to maintain its current cash runway, as the lack of positive operating cash flow necessitates a reliance on external financing.
The P/S ratio is the most commonly misapplied metric for MDBH, as it obscures the firm's deeply negative gross margins and the fact that a significant portion of revenue is non-recurring and highly concentrated in project-based advisory fees.
Using revenue multiples to value this business model ignores the reality that the firm is essentially a cash-burning incubator rather than a scalable financial services platform. A more appropriate approach would involve a sum-of-the-parts valuation that separates the broker-dealer's cash-flow-generating potential from the speculative, high-risk value of the synthetic biology intellectual property.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MDBH stock.
MDB Capital Holdings, LLC Class A common's current P/E ratio is -1.5x. The historical average is 2.4x.
MDB Capital Holdings, LLC Class A common's return on equity (ROE) is -32.5%. The historical average is -28.1%.
Based on historical data, MDB Capital Holdings, LLC Class A common is trading at a P/E of -1.5x. Compare with industry peers and growth rates for a complete picture.
MDB Capital Holdings, LLC Class A common has -249.6% gross margin and -408.5% operating margin.